<DOC>
	<DOCNO>NCT01467687</DOCNO>
	<brief_summary>The purpose study determine bioequivalency Synerx Pharma Verapamil extend release capsule .</brief_summary>
	<brief_title>Comparative Bioavailability Study Synerx Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions</brief_title>
	<detailed_description>The purpose study determine Synerx Pharma Verapamil HCl ER Capsules bioequivalent Verelan PM capsule healthy volunteer food effect condition .</detailed_description>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Healthy adult male female volunteer , 1855 year age . Subjects continuous nonsmoker least 3 month prior first dose . Weighing least 60 kg male 52 kg female within normal range accord accept normal value Body Mass Index Chart ( 18.00 28.00 kg/m2 ) . Medically healthy subject clinically normal laboratory profile , vital sign ECGs . Absence exclusion criterion history , physical , laboratory evaluation . Confirmation female subject pregnant certify , validated pregnancy test . Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study acceptable birth control method Postmenopausal woman amenorrhea least 2 year eligible . Give voluntary write informed consent participate study . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : alcoholism drug abuse within past year ; hypersensitivity idiosyncratic reaction verapamil , calcium ion influx inhibitor component product formulation ; idiosyncratic reaction acetaminophen ; malabsorption within past year ; recurrent headache migraine . Presence medical condition require regular treatment prescription drug . Tests give reasonable suspicion disease would contraindicate take investigational drug might affect interpretation result study . Female subject pregnant lactating . Subjects test positive screening HIV , HbsAg HCV . Positive test result drug abuse alcohol . Subjects whose sit blood pressure le 110/60 mmHg screen 100/55 mmHg prior dosing period . Subjects whose pulse low 55 b.p.m . screen 50 b.p.m . prior dosing period . Subjects whose PR interval &gt; 190 msec screen &gt; 200 msec prior dosing period . Subjects whose QTc interval &gt; 450 msec screen prior dosing period . Subjects use drug substance know strong inducer and/or inhibitor CYP enzymes within 28 day prior first dose . Subjects special diet 28 day prior first dose throughout study . Subjects donate 50 499 mL blood within 30 day 499 mL within 56 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>